Editor: Ian Henderson
Respiratory ATP synthesis: the new generation of mycobacterial drug targets?
Article first published online: 20 MAR 2010
© 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved
FEMS Microbiology Letters
Volume 308, Issue 1, pages 1–7, July 2010
How to Cite
Bald, D. and Koul, A. (2010), Respiratory ATP synthesis: the new generation of mycobacterial drug targets?. FEMS Microbiology Letters, 308: 1–7. doi: 10.1111/j.1574-6968.2010.01959.x
- Issue published online: 1 JUN 2010
- Article first published online: 20 MAR 2010
- Received 23 November 2009; revised 26 February 2010; accepted 11 March 2010.Final version published online 14 April 2010.
- ATP synthesis;
- respiratory chain;
- antimycobacterial drugs
Mycobacterium tuberculosis, the causative agent of tuberculosis, poses a global health challenge due to the emergence of drug-resistant strains. Recently, bacterial energy metabolism has come into focus as a promising new target pathway for the development of antimycobacterial drugs. This review summarizes our current knowledge on mycobacterial respiratory energy conversion, in particular, during the physiologically dormant state that is associated with latent or persistent tuberculosis infections. Targeting components of respiratory ATP production, such as type-2 NADH dehydrogenase or ATP synthase, is illustrated as an emerging strategy in the development of novel drugs.